Search details
1.
CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition.
Nature
; 604(7907): 749-756, 2022 04.
Article
in English
| MEDLINE | ID: mdl-35444283
2.
GPR105 ablation prevents inflammation and improves insulin sensitivity in mice with diet-induced obesity.
J Immunol
; 189(4): 1992-9, 2012 Aug 15.
Article
in English
| MEDLINE | ID: mdl-22778393
3.
Discovery of the Potent and Selective ATR Inhibitor Camonsertib (RP-3500).
J Med Chem
; 67(4): 2349-2368, 2024 Feb 22.
Article
in English
| MEDLINE | ID: mdl-38299539
4.
RP-3500: A Novel, Potent, and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors.
Mol Cancer Ther
; 21(2): 245-256, 2022 02.
Article
in English
| MEDLINE | ID: mdl-34911817
5.
Discovery of an Orally Bioavailable and Selective PKMYT1 Inhibitor, RP-6306.
J Med Chem
; 65(15): 10251-10284, 2022 08 11.
Article
in English
| MEDLINE | ID: mdl-35880755
6.
Identification of RP-6685, an Orally Bioavailable Compound that Inhibits the DNA Polymerase Activity of Polθ.
J Med Chem
; 65(19): 13198-13215, 2022 10 13.
Article
in English
| MEDLINE | ID: mdl-36126059
7.
Applying the pro-drug approach to afford highly bioavailable antagonists of P2Y(14).
Bioorg Med Chem Lett
; 21(14): 4366-8, 2011 Jul 15.
Article
in English
| MEDLINE | ID: mdl-21689930
8.
The identification of 4,7-disubstituted naphthoic acid derivatives as UDP-competitive antagonists of P2Y14.
Bioorg Med Chem Lett
; 21(10): 2836-9, 2011 May 15.
Article
in English
| MEDLINE | ID: mdl-21507640
9.
Synthesis and SAR of pyrimidine-based, non-nucleotide P2Y14 receptor antagonists.
Bioorg Med Chem Lett
; 21(10): 2832-5, 2011 May 15.
Article
in English
| MEDLINE | ID: mdl-21507642
10.
Connexin43 pseudogene in breast cancer cells offers a novel therapeutic target.
Mol Cancer Ther
; 8(4): 786-93, 2009 Apr.
Article
in English
| MEDLINE | ID: mdl-19372551
11.
[When translation arises from its TORpor]. / Quand la traduction sort de sa TORpeur.
Med Sci (Paris)
; 22(5): 514-8, 2006 May.
Article
in French
| MEDLINE | ID: mdl-16687120
12.
Disruption of the B-cell specific transcriptional program in HHV-8 associated primary effusion lymphoma cell lines.
Oncogene
; 22(7): 964-73, 2003 Feb 20.
Article
in English
| MEDLINE | ID: mdl-12592383
13.
eIF4E--from translation to transformation.
Oncogene
; 23(18): 3172-9, 2004 Apr 19.
Article
in English
| MEDLINE | ID: mdl-15094766
14.
Repression of IRF-4 target genes in human T cell leukemia virus-1 infection.
Oncogene
; 21(44): 6751-65, 2002 Oct 03.
Article
in English
| MEDLINE | ID: mdl-12360402
15.
Repression of DNA repair mechanisms in IRF-4-expressing and HTLV-I-infected T lymphocytes.
J Interferon Cytokine Res
; 25(1): 43-51, 2005 Jan.
Article
in English
| MEDLINE | ID: mdl-15684621
16.
IRF-4 activities in HTLV-I-induced T cell leukemogenesis.
J Interferon Cytokine Res
; 22(1): 135-43, 2002 Jan.
Article
in English
| MEDLINE | ID: mdl-11846984
17.
The C3a anaphylatoxin receptor is a key mediator of insulin resistance and functions by modulating adipose tissue macrophage infiltration and activation.
Diabetes
; 58(9): 2006-17, 2009 Sep.
Article
in English
| MEDLINE | ID: mdl-19581423
18.
p53-dependent translational control of senescence and transformation via 4E-BPs.
Cancer Cell
; 16(5): 439-46, 2009 Nov 06.
Article
in English
| MEDLINE | ID: mdl-19878875
19.
Epigenetic activation of a subset of mRNAs by eIF4E explains its effects on cell proliferation.
PLoS One
; 2(2): e242, 2007 Feb 21.
Article
in English
| MEDLINE | ID: mdl-17311107
20.
IFN regulatory factor 4 participates in the human T cell lymphotropic virus type I-mediated activation of the IL-15 receptor alpha promoter.
J Immunol
; 168(11): 5667-74, 2002 Jun 01.
Article
in English
| MEDLINE | ID: mdl-12023365